Spyre Therapeutics Announces Positive Phase 1 Results for Anti-TL1A Antibody Programs and Phase 2 Clinical Development Plans
Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two investigational, extended half-life monoclonal antibodies tar...